EASL recommendations on treatment of hepatitis C: Final update of the series
EASL recommendations on treatment of hepatitis C: Final update of the series
复制标题
DOI：
10.1016/j.jhep.2020.08.018
复制
发表时间：
2020-11-01
影响因子：
25.7
通讯作者：
Wedemeyer, Heiner
中科院分区：
文献类型：
--
作者：
Pawlotsky, Jean-Michel;Negro, Francesco;Wedemeyer, Heiner
丙型肝炎病毒（HCV）感染是慢性肝病的主要原因，全世界约有7100万慢性感染者。HCV相关肝病患者的临床护理已经取得了相当大的进展，这要归功于对该疾病病理生理学的深入了解，以及诊断程序的发展和治疗和预防的改进。根据世界卫生组织的目标，这些疗法可以消除丙型肝炎作为一种主要的公共卫生威胁，尽管时间轴和可行性因地区而异。这些欧洲肝脏研究协会关于丙型肝炎治疗的建议描述了2020年及以后近期获得性和慢性HCV感染患者的最佳管理。(C)2020年欧洲肝脏研究协会。Elsevier B.V.出版，保留所有权利。
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.